Jöerg Schubert

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Medicine, Immunology, Oncology +7

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Kirsten Fischer, Paula Cramer, Raymonde Busch et al. · Journal of Clinical Oncology · 2012 · 431 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection

Sanna Aalto, Kimmo Linnavuori, Heikki Peltola et al. · Journal of Medical Virology · 1998 · 130 citations

Veterinary Medicine, Immunology, Infectious Diseases +14

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt et al. · Blood · 2010 · 88 citations

Medicine, Oncology, Pharmacotherapy +16

Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells

Christian Kellner, Joerg Bruenke, Heike Horner et al. · Cancer Letters · 2011 · 44 citations

Pharmacy, Immunology, Oncology +14